CurifyLabs Raises $14 Million Series A to Advance Personalized Medicine Technology

CurifyLabs has raised $14 million in a Series A funding round announced in a press release. The round was co-led by Sandwater and HealthCap, with participation from Tesi, Lifeline Ventures, and other investors in the U.S. and Europe.

The funds will be used to expand CurifyLabs' operations in the United States, strengthen supply chain infrastructure, enhance customer support, and accelerate product development. The company’s Compounding System Solution combines proprietary software, GMP-manufactured excipients, and 3D printing technology to automate the preparation of personalized medicines.

CurifyLabs serves pharmacies in 21 U.S. states and across Europe, enabling them to produce thousands of tailored doses daily. The funding will support further development of its platform, including the PharmaPrinter Aurum, which compounds medication up to nine times faster than manual methods. The technology is ISO 13485 certified and designed to comply with FDA 503A and 503B standards for non-sterile compounding.